HSDD affects 40%-55% of postmenopausal women, often due to hormonal changes, impacting sexual desire and quality of life.

Menopausal hormone therapy (MHT) does not raise breast cancer risk in women with breast cancer gene mutations, while estrogen only MHT leads to reduced risk.

U.S. health officials have expanded approval of a drug that boosts libido in women who report stress due to a low sex drive.

Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Courtney Cameron, PharmD, BCACP, about widespread availability of ...